Impact of metabolic phenotype changes on the development of chronic kidney disease: Panasonic cohort study 17

Fuente: Wiley Open Access
Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Junya Hironaka, Hiroshi Okada, Tetsuro Kusaba, Hanako Nakajima, Emi Ushigome, Masahide Hamaguchi, Kazushiro Kurogi, Hiroaki Murata, Naoki Yoshida, Masato Ito, Michiaki Fukui
Format: Artículo Open Access
Veröffentlicht: Wiley 2025
Schlagworte:
Online-Zugang:
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1867016598220439552
author Junya Hironaka
Hiroshi Okada
Tetsuro Kusaba
Hanako Nakajima
Emi Ushigome
Masahide Hamaguchi
Kazushiro Kurogi
Hiroaki Murata
Naoki Yoshida
Masato Ito
Michiaki Fukui
author_facet Junya Hironaka
Hiroshi Okada
Tetsuro Kusaba
Hanako Nakajima
Emi Ushigome
Masahide Hamaguchi
Kazushiro Kurogi
Hiroaki Murata
Naoki Yoshida
Masato Ito
Michiaki Fukui
Junya Hironaka
Hiroshi Okada
Tetsuro Kusaba
Hanako Nakajima
Emi Ushigome
Masahide Hamaguchi
Kazushiro Kurogi
Hiroaki Murata
Naoki Yoshida
Masato Ito
Michiaki Fukui
collection Wiley Open Access
contents Impact of metabolic phenotype changes on the development of chronic kidney disease: Panasonic cohort study 17 Junya Hironaka Hiroshi Okada Tetsuro Kusaba Hanako Nakajima Emi Ushigome Masahide Hamaguchi Kazushiro Kurogi Hiroaki Murata Naoki Yoshida Masato Ito Michiaki Fukui Obesity AbstractObjectiveThis study investigated how changes in metabolic phenotype, defined by obesity and metabolic health, impact chronic kidney disease (CKD) development in a large cohort.MethodsA retrospective cohort study analyzed health data collected between 2011 and 2021 from 84,729 Panasonic Holdings Corporation (formerly Panasonic Corporation) employees aged ≥40 years. Metabolic phenotypes were classified as metabolically healthy with no obesity (MHNO), metabolically healthy with obesity (MHO), metabolic abnormalities with no obesity (MANO), and metabolic abnormalities with obesity (MAO). Changes in metabolic phenotype over 3 years and their association with CKD development were assessed using Cox proportional hazards models adjusted for confounding variables.ResultsDuring a mean follow‐up of 5.1 years, a total of 12,172 of participants (14.4%) developed CKD. Transitioning from MHO to MHNO and from MAO to MANO did not reduce CKD risk compared to each stable group. In contrast, participants in the MANO‐to‐MHNO and MAO‐to‐MHO groups significantly lowered CKD risk relative to each stable group, with hazard ratios of 0.86 (95% CI: 0.77–0.96) and 0.83 (95% CI: 0.67–1.02), respectively. The same results were observed when a rapid decline in renal function was used as the outcome.ConclusionsThe improvement of metabolic profile might outweigh weight reduction in CKD risk. 10.1002/oby.24293 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/oby.24293
format Artículo Open Access
id wiley_oa_10_1002_oby_24293
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Impact of metabolic phenotype changes on the development of chronic kidney disease: Panasonic cohort study 17
Junya Hironaka
Hiroshi Okada
Tetsuro Kusaba
Hanako Nakajima
Emi Ushigome
Masahide Hamaguchi
Kazushiro Kurogi
Hiroaki Murata
Naoki Yoshida
Masato Ito
Michiaki Fukui
Obesity
Impact of metabolic phenotype changes on the development of chronic kidney disease: Panasonic cohort study 17 Junya Hironaka Hiroshi Okada Tetsuro Kusaba Hanako Nakajima Emi Ushigome Masahide Hamaguchi Kazushiro Kurogi Hiroaki Murata Naoki Yoshida Masato Ito Michiaki Fukui Obesity AbstractObjectiveThis study investigated how changes in metabolic phenotype, defined by obesity and metabolic health, impact chronic kidney disease (CKD) development in a large cohort.MethodsA retrospective cohort study analyzed health data collected between 2011 and 2021 from 84,729 Panasonic Holdings Corporation (formerly Panasonic Corporation) employees aged ≥40 years. Metabolic phenotypes were classified as metabolically healthy with no obesity (MHNO), metabolically healthy with obesity (MHO), metabolic abnormalities with no obesity (MANO), and metabolic abnormalities with obesity (MAO). Changes in metabolic phenotype over 3 years and their association with CKD development were assessed using Cox proportional hazards models adjusted for confounding variables.ResultsDuring a mean follow‐up of 5.1 years, a total of 12,172 of participants (14.4%) developed CKD. Transitioning from MHO to MHNO and from MAO to MANO did not reduce CKD risk compared to each stable group. In contrast, participants in the MANO‐to‐MHNO and MAO‐to‐MHO groups significantly lowered CKD risk relative to each stable group, with hazard ratios of 0.86 (95% CI: 0.77–0.96) and 0.83 (95% CI: 0.67–1.02), respectively. The same results were observed when a rapid decline in renal function was used as the outcome.ConclusionsThe improvement of metabolic profile might outweigh weight reduction in CKD risk. 10.1002/oby.24293 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Impact of metabolic phenotype changes on the development of chronic kidney disease: Panasonic cohort study 17
topic Obesity
url https://onlinelibrary.wiley.com/doi/10.1002/oby.24293